Bridging Literature and Real-World Evidence: External Evaluation and Development of Fluoxetine Population Pharmacokinetics Model
Pharmaceutics · 24.11.2025 · 17 (12) · 1516
DOI: 10.3390/pharmaceutics17121516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 24.11.2025. Verfasst von Bing Han und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Medical Specialty Project of Minhang District, Medical Specialty Project of Minhang District.
Abstract (Originalsprache)
Background
Fluoxetine is widely prescribed to treat depression but exhibits high inter-individual and inter-ethnic pharmacokinetic (PK) variability. Most published population pharmacokinetic (PopPK) models were derived from Western patients, and their applicability to Chinese patients remains uncertain.
Methods
A systematic review of the published fluoxetine PopPK models was carried, and the relevant demographic and model parameters were extracted. A retrospective real-world dataset from Chinese psychiatric patients was then collected. External evaluation was conducted to assess the model’s predictive performance. Subsequently, a joint parent–metabolite PopPK model was developed to better characterize fluoxetine and its active metabolite norfluoxetine in Chinese patients. Finally, Monte Carlo simulations were performed to evaluate once-daily dosing regimens of 10–60 mg for 30 days, focusing on the probability of achieving target (PTA) steady-state trough concentrations (Cmin,ss).
Results
Two published PopPK models were identified and externally evaluated using data from 198 Chinese patients with 241 fluoxetine and 241 norfluoxetine plasma concentrations. Both models were shown to have prediction discrepancy. The parent drug–metabolite model was used to describe the characteristics of fluoxetine and norfluoxetine in the Chinese population. Sex was identified as the significant covariate, and males exhibited a 16.5% higher clearance than females. The simulation results indicate that the maximum effective dose for females is 30 mg once daily, and for males, it is 40 mg once daily.
Conclusions
This study provides the first comprehensive external evaluation of published fluoxetine PopPK models and establishes a tailored joint model that incorporates sex effects to explain trough variability in Chinese psychiatric patients. The findings support 30–40 mg once daily as a practical dosing range for Chinese adults and adolescents, with males more likely to require the higher dose.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Fudan University, Shanghai 201203, China.
- Department of Clinical Pharmacology and Clinical Trial, The Second People's Hospital of Hunan Province (Brain Hospital of Hunan Province), Changsha 410007, China.
- Institute of Big Data, Central South University, Changsha 410083, China.
- Department of Medical Laboratory, Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, Changsha 410007…
- Minhang Hospital, Fudan University, Shanghai 201100, China.
- State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai 201203, China.
Förderung
- the Medical Specialty Project of Minhang District
- Medical Specialty Project of Minhang District
Zitieren
APA
Han, B., Xu, N., Ma, C., Ju, G., Xi, X., Qian, C., Guo, N., Liu, X., Zhu, X., Li, C., & Liu, L. (2025). Bridging Literature and Real-World Evidence: External Evaluation and Development of Fluoxetine Population Pharmacokinetics Model. Pharmaceutics, 17(12), 1516. https://doi.org/10.3390/pharmaceutics17121516
Vancouver
Han B, Xu N, Ma C, Ju G, Xi X, Qian C, et al. Bridging Literature and Real-World Evidence: External Evaluation and Development of Fluoxetine Population Pharmacokinetics Model. Pharmaceutics. 2025;17(12):1516. doi:10.3390/pharmaceutics17121516
BibTeX
@article{Han2025,
author = {Han, Bing and Xu, Nuo and Ma, Chen and Ju, Gehang and Xi, Xie and Qian, Cheng and Guo, Nan and Liu, Xin and Zhu, Xiao and Li, Cong and Liu, Li},
title = {Bridging Literature and Real-World Evidence: External Evaluation and Development of Fluoxetine Population Pharmacokinetics Model},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {12},
pages = {1516},
doi = {10.3390/pharmaceutics17121516}
}
EUVIMED